Curasight A/S presents at Økonomisk Ugebrev Life Science Investor Conference
Curasight A/S CEO Ulrich Krasilnikoff will present the company and its future plans, at Økonomisk Ugebrev Life Science Investor Conference 10 March 2021. The presentation will be webcasted live.
For more information – please click here
For more information regarding Curasight, please contact:
Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.